Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Arrys Therapeutics

Arrys Therapeutics?uq=K9LEA9hy
PRIVATE STATUS
Series A LATEST DEAL TYPE
$21M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of immuno-metabolism therapy deigned to translate high impact science into medicines for patients. The company's immuno-metabolism therapy in human clinical studies for non-oncology indications and holds a program called ARY-007, enabling patients to treat cancer treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
  • 1030 Massachusetts Avenue
  • Suite 400
  • Cambridge, MA 02138
  • United States

+1 (857) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Arrys Therapeutics’s full profile, request a free trial.

Arrys Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 14-Dec-2017 $21M 0000 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Arrys Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00 00 00 00 00 000
To view this company’s complete Cap Table, request access »

Arrys Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Atlas Venture Venture Capital Minority 000 0000 000000 0
OrbiMed Venture Capital Minority 000 0000 000000 0

Arrys Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Iain Dukes President & Chief Executive Officer